Open an account

Onconetix

ONCO · NASDAQ

$0.4064−$0.0239 (−5.55%)TodayMarket closed ·
Prev close $0.4303

About ONCO

Onconetix, Inc. is a commercial stage biotechnology company, which engages in the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. The company is headquartered in Cincinnati, Ohio and currently employs 2 full-time employees. The company went IPO on 2022-02-18. The firm owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test.

Employees
5
Headquarters
Cincinnati, Ohio
Listed
Feb 18, 2022
Sector
Health Care
Industry
Biotechnology
Website
onconetix.com

ONCO key statistics

Market cap
2.13M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
7.26M
Volume
334.57K
Open price
$0.4285
High today
$0.4288
Low today
$0.3801
52 Week high
$200.00
52 Week low
$0.4221

Onconetix (ONCO) at a glance

Onconetix (ONCO) last traded at $0.4064, with a market cap of 2.13M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.3801 and $0.4288. The current price is 6.9% above the day's low and 5.2% below its high.

Volume so far is 334.57K shares, below the average of 7.26M shares a day.

Over the past year Onconetix has ranged from $0.4221 to $200.00, and now sits 0% of the way up that range.

Onconetix met or beat analyst EPS estimates in 3 of the last 5 quarters. In Q1 FY25 it reported $0.25 per share against an estimate of $0.00.

ONCO earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 5 quarters, by 14.2% on average.

  1. Q4 FY22: reported -$33,660.00 per share against an estimate of -$45,951.00
  2. Q1 FY23: reported -$30,600.00 per share against an estimate of -$36,414.00
  3. Q2 FY23: reported -$35,700.00 per share against an estimate of -$26,010.00
  4. Q3 FY23: reported -$45,900.00 per share against an estimate of -$32,946.00
  5. Q1 FY25: reported $0.25 per share against an estimate of $0.00

ONCO news

  • 12 Health Care Stocks Moving In Tuesday's After-Market Session

  • Avi Kapoor

    Why INLIF Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket

  • Press releaseBusiness Wire

    Realbotix Reports Financial Results for Q3-2026

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

  • Press releaseBusiness Wire

    Realbotix Corp. Provides Corporate Structure and Operations Update

  • Press releaseBusiness Wire

    Realbotix Reports Financial Results for Q2-2026

  • Avi Kapoor

    Gold Falls 1%; Amer Sports Earnings Top Views

  • Avi Kapoor

    Dow Falls Over 100 Points; Home Depot Posts Upbeat Earnings

Similar companies

Companies in the same industry as Onconetix

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.